San Francisco, United States
Anubis Bio, founded in 2018 and headquartered in the United States, operates in the Biotechnology, Health Care, Health and Wellness, and Nutrition industries. The company offers a unique Patented Microbiome-Cleanser (TM) food platform designed to quickly resolve distress diarrhea in animals, primarily focusing on dogs. This innovation serves to enhance and maintain animal immune and gastrointestinal systems.
Anubis Bio distinguishes itself with its USPTO-patented technology, providing a substantial competitive advantage. In Q1 2021, the company secured two significant B2B distribution partnerships, enhancing its market reach and growth potential. The company's last financial milestone was a $1.00M Seed Round investment on 20 March 2020, with backing from Life Science Angels and Freada Kapor Klein.
These elements position Anubis Bio as a promising investment opportunity with a strong technological foundation and promising growth trajectory.
